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BACKGROUND: Simian virus-40 (SV40) is a DNA tumour virus that was introduced into the human population with contaminated
poliovirus vaccine, and its role in mesothelioma is widely debated. PCR based testing has been called into question, as false positives
can be because of cross-reactivity with related viruses, or to laboratory contamination. The Institute of Medicine has recommended
the development of more sensitive and specific tests to resolve this controversy.
METHODS: We have characterized highly sensitive RT–PCR based assays that are specific for SV40-encoded microRNAs (miRNAs),
as an alternative to current testing methods.
RESULTS: Using this sensitive and specific detection method, we were unable to identify SV40 miRNA expression in human malignant
pleural mesothelioma (MM) samples.
CONCLUSION: Our work indicates that SV40 miRNAs are not likely to contribute to mesothelioma tumourogenesis, but highlights the
value of this approach when compared with the relatively unspecific current testing methods.
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Simian virus-40 (SV40) is a monkey polyomavirus that was first
introduced into the human population in the 1950s with
contaminated poliovirus vaccine, and continued until at least the
early 1970s (Sweet and Hilleman, 1960). SV40 has been shown to
cause tumours in hamsters and sporadically produce small
quantities of infectious virus (Eddy et al, 1961; Sabin and Koch,
1963). The transforming roles of the early viral proteins, large T
antigen and small t antigen, have been clearly established in vitro
(Frisque et al, 2006; Khalili et al, 2008). The fact that SV40 can
have cytopathic effects and can transform human cells has led to
the debate as to whether this virus can cause cancer in humans.
Notably, SV40 has been implicated as a co-carcinogen in MM.
Published reports have detected SV40 DNA in up to 50% of MM
patients (Carbone et al, 1994). In 2002, a study was published by
the Immunization Safety Review Committee of the United States
Institute of Medicine, which explored the correlation between
SV40 exposure and human cancers. The conclusion was that the
evidence was inadequate to determine a causal relationship but did
recommend the development of sensitive and specific serological
tests for the virus (Stratton et al, 2002).
A recent report has demonstrated that SV40-encoded micro-
RNAs (miRNA) are expressed in infected cells (Sullivan et al,
2005). The five known SV40 miRNAs are different length splice
variants produced from the 50 and 30 arms of a precursor miRNA,
derived from the late transcript, a portion generally not included in
laboratory plasmids. SV40 miRNAs are distinguishable from the
miRNAs encoded by the closely related human polyomaviruses,
with the 50 and 30 mature sequences having only 50 and 77%
identity to the JCV and BKV sequences (Seo et al, 2008). For these
reasons, we concentrated on the SV40-encoded miRNAs to develop
a more sensitive and reliable SV40 detection technique.
METHODS
Viruses and cell lines
We used SVG-A cells, a subclone of SVG cells (ATCC no.
CRL-8621), an SV40-transformed human astroglial cell line and
SV-T2 cells (ATCC no. CCL-163.1, Manassas, VA, USA), a mouse
fibroblast cell line transformed with SV40. We also used SV40-
negative human embryonic kidney cells (HEK)-293 cells (ATCC
no. CRL-1573), a human kidney cell line transformed with
adenovirus 5 DNA. All cell lines were grown in ATCC recom-
mended media supplemented with foetal bovine serum under
standard conditions.
Tissue ascertainment
Fresh frozen tissues were obtained from the CREST Biorepository
of the National Cancer Research Institute, Genova, Italy, the
Masonic Cancer Center’s Tissue Procurement Facility at the
University of Minnesota, the National Mesothelioma Virtual Bank,
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sthe tumour bank at Rhode Island Hospital and the National
Disease Research Interchange. The samples consisted of non-
malignant biopsies (n¼28), pleural biopsies from lung adenocar-
cinoma patients (n¼20) and a mixture of 94 mesothelioma
tumour samples, made up of epithelioid (n¼42), biphasic (n¼18)
sarcomatoid (n¼10) and non-histologically defined mesothelioma
patients (n¼24). Data on patient age was not available for all
samples, but for known tumours, the average patient age was 62.3
years for mesotheliomas and 75.2 years for lung adenocarcinomas
and matched normal tissue.
Infections and RNA isolation
Cells were grown to 70% conuence on coverslips and incubated
with 1 10
5 PFU of SV40 (wild type strain 777) per 1 10
6 cells for
1h at 371C. At the end of the incubation, cells were washed and fed
with Eagle’s minimal essential medium for up to 96h. The media
was then aspirated off and cells were detached with trypsin-EDTA
for 5min at 37
oC. Cells were pelleted and washed two times with
cold PBS. Infections were performed in triplicate and three
samples of 1 10
6 cells were harvested and transferred to a clean
tube and pelleted. RNA extractions were performed using the
Ambion mirVana miRNA Isolation Kit (cat no. AM1561, Applied
Biosystems/Ambion, St. Austin, TX, USA) according to the
manufacturer’s instructions for total RNA and small RNA-
enriched fractions. All live virus work was performed in a
laboratory separate from RNA and PCR work.
Quantitative PCR assays and kits
RNA Oligonucleotides were purchased from Invitrogen Corporation,
Carlsbad, CA, USA and IDT (Integrated DNA Technologies, Inc.,
Coraville, IA, USA). All miRNA assays were purchased from
(Applied Biosystems, Foster City, CA, USA). Human: RNU44 (part
no. 4373384), RNU48 (part no. 4373383), RNU6B (part no. 4373381).
Mouse: snoRNA202 (part no. 4380914). Viral specific miRNA assays
are based on 50 and 30 mature miRNA sequences and are available to
purchase from Applied Biosystems. Assay validations were per-
formed on using synthetic RNA oligos diluted to 10mM in water. A
total of 5ml of oligo was reverse transcribed and amplified by
quantitative PCR in triplicate according to the manufacturer’s
directions to test the specificity of each miRNA assay. Experiments
on cell lysates used 10ng of total RNA or RNA enriched for small
RNAs as template. All cDNA synthesis and quantitative PCR were
performed according the manufacturers’ conditions and run on an
Applied Biosystems’ 7300 Real Time PCR System. TaqMan
MicroRNA Reverse Transcription Kit, 1000 reactions (part no.
4366597), High Capacity cDNA Reverse Transcription Kit with
RNase Inhibitor, 200 Reactions (part no. 4374966), TaqMan
Universal PCR Master Mix, No AmpErase UNG, 1-Pack (1 5ml;
part no. 4324018) were used.
RESULTS
Assay validation
We used custom real-time quantification PCR assays developed by
Applied Biosystems that employ a stem-loop real-time PCR primer
for the specific detection of mature miRNA (Chen et al, 2005). This
approach allows for highly specific detection of the active miRNA
product, rather than an inconclusive result in the detection of the
longer, unspliced, pre-miRNA. Five specific assays were developed,
one for each of the three different 50 splice variants (50AC, 50Ca n d5 0)
and one each for the two different 30 splice variants (30C and 30).
Each assay was validated using cDNA made from 10nM dilutions
of synthetic RNA oligonucleotides (Figure 1). The assays were
tested for fidelity with synthetic RNA oligonucleotides containing
either one or two mismatches to the minimal 50 and 30 sequences
(Figure 1D). Neither the 50 assay nor the 30 assay could detect
differences between the minimal miRNA and the longer splice
variants, but they were specific for the sequences themselves.
Each assay discriminated the mismatched oligonucleotides,
although the position of the mismatches influenced the sensitivity
of the assays. The single mismatch U-G had less cross-reactivity
in both cases than the combined U-A and U-C mismatches.
Owing to the ability of the minimal 50 and 30 assays to detect the
longer respective miRNA splice variants, the minimal assays were
used in all future experiments (Figures 1A and 1B). Dilutions of the
minimal synthetic 50 and 30 RNA oligos were used to measure the
sensitivity of the assays, which are linear over multiple orders of
magnitude (Figure 1C).
SV40 miRNAs are not expressed in transformed cells
We next used SV40-transformed mouse (SV-T2) and human (SVG-A)
cell lines to test the sensitivity of all five assays compared with the
species-specific small RNAs, snoRNA202 (mouse) and RNU48
(human). These cells contain at least one copy of the entire genome
but do not express the late transcript and therefore should not
express the mature miRNAs (Botchan et al, 1976; Major and
Matsumura, 1984). We compared the background detection of
each assay in small RNA-enriched lysates of both cell types and
found that both the 50 and 30 assays detected o1% of the relative
control (Figure 2). The minimal assays had the least cross-
reactivity in transformed cell lines with the 30 and 50 assays being
specific to 100fM and 300fM, respectively.
SV40 miRNA expression in infected human cells
We chose the minimal 50 and 30 assays to detect miRNA in actively
infected cells following SV40 infection of human embryonic kidney
cells HEK and measured the expression over time. We found that
the 30 miRNA was first detected 48h after infection. The level
continued to increase over 96h of the initial round of infection in
accordance with the known timeline of late transcription (Figure 3).
In these cells, the 50 transcript was undetectable during the entire
96-h time course (data not shown).
SV40 miRNA not detected in human mesothelioma
biopsies
We used the minimal 50 and 30 assays to detect the expression of
SV40-encoded miRNAs in 94 human malignant mesothelioma
tumour biopsies as well as in 20 lung adenocarcinoma cancerous
and 28 non-malignant control biopsies (Figure 4). Despite the high
sensitivity of these assays, we were unable to find any evidence of
SV40 miRNA expression in human tissues. To ensure that the lack
of SV40 miRNA expression in mesotheliomas was not because of
technical problems isolating miRNA from these tissue samples, or
to a general miRNA processing defect of this tumour type, we used
quantitative PCR to detect three separate host-encoded miRNAs
in mesotheliomas compared with non-malignant lung tissue
(Supplementary Figure 1).
CONCLUSION
We characterized sensitive and specific quantitative PCR assays
that are based on the expression of the mature SV40-encoded
miRNAs. We showed that, although the assays cannot distinguish
the minimal 50 and 30 miRNAs from the longer splice variants, the
assays are highly sensitive to sequence. Single mismatches in the
detected sequence result in decreased amplification. We used
synthetic oligonucleotides to make standard curves and show that
both minimal 50 and 30 assays are sensitive over many orders of
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smagnitude. We also used SV40-transformed and non-SV40-
transformed cell lines to characterize the levels and timeline of
miRNA expression following infection with the virus.
Our results indicated that these assays were both sensitive and
specific enough to meet the standard for serological SV40 tests
recommended by the Institute of Medicine. We have tested these
1.0e+001 A B
D C
1.0e+000
1.0e-001
Cycle number
60
50
40
30
20
10
0
R
2=0.9854
R
2=0.9903
Amount of target (M)
1E-16 1E-15 1E-14 1E-13 1E-12 1E-11 1E-10 1E-09 1E-08
C
t
 
v
a
l
u
e
3′ Assay
5′ Assay
Name
5′AC
5′C
5′
5′M1
5′M2
3′C
3′
3′M1
3′M2
RNA oligo sequence
ACUGAGGGGCCUGAAAUGAGCCUU
CUGAGGGGCCUGAAAUGAGCCUU
UGAGGGGCCUGAAAUGAGCCUU
UGAGGGGCCgGAAAUGAGCCUU
aGAGGGGCCUGAAAcGAGCCUU
GCCUGUUUCAUGCCCUGAGUC
GCCUGUUUCAUGCCCUGAGU
GCCUGUUUCAUGCCCgGAGU
GCCUGUUUCAcGCCCUGAGa
5′
5′C
5′AC
3′
3′C
M1 M2
D
e
l
t
a
 
R
n
1.0e+001
1.0e+000
1.0e-001
D
e
l
t
a
 
R
n
NTC
Cycle number
M2
M1
NTC
Figure 1 MicroRNA assay validation. Assays designed against the minimal 50 and 30 miRNA sequences were tested using synthetic RNA oligonucleotides.
(A) The assay designed against the minimal 50 miRNA sequence was tested using the 50,5 0Ca n d5 0AC synthetic oligos as well as 50M1, a mismatched oligo
otherwise identical to 50 with a U-G substitution at position 10, and 50M2, a oligo mismatched to 50 with a U-A substitution at position 1 and a U-C
substitution at position 15. (B) The assay designed against the minimal 30 miRNA sequence was tested using the 30,a n d3 0C synthetic oligos as well as 30M1, a
mismatched oligo otherwise identical to 30 with a U-G substitution at position 16, and 30M2, a mismatched oligo to 30 with a U-C substitution at position 11
and a U-A substitution at position 20. Amplification plots reveal that neither the 50 nor the 30 assay can differentiate between the minimal and longer mature
miRNAs but they are specific for the sequences. The experiment was repeated using assays designed against the longer 50AC, 50Ca n d3 0C miRNA sequences.
These yielded results similar to the assays designed against the minimal sequences (data not shown). (C) qRT–PCR was performed on serial dilutions of RNA
oligos to determine the linearity of the assay over several orders of magnitude. (D) The sequences of RNA oligos used to test each assay. Mismatched nucleotides
are shown in lowercase.
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Figure 2 Relative background detection in SV40-transformed cell lines. Assays against the various miRNAs were tested for fidelity using the mouse SV40-
transformed cell line, SV-T2, and the human SV40-transformed cell line, SVG-A. Cell lysates enriched for small RNAs were reverse transcribed using each
specific assay. Quantitative PCR was performed to measure the levels of each SV40 miRNA in relation to the mouse control small RNA, snoRNA202, and
the human control small RNA, RNU48. Error bars represent the s.e. of two experiments for SV-T2 cells or three experiments for SVG-A cells. The relative
quantification of miRNA was performed according to the 2
 DDCt method, comparing product amplified from mouse cells relative to snoRNA202, and
product amplified from human cells relative to RNU48.
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sassays on 94 different human MM samples from multiple tissue
banks. Using the 50 and 30 assays, we were unable to detect SV40
miRNAs in any human tissue samples. The initial paper describing
these miRNAs suggested that they may function to downregulate
SV40 early protein expression and allow the virus to escape
immune clearance (Sullivan et al, 2005). This led us to postulate
that these miRNAs may be detectable in mesotheliomas and could
provide a useful target to develop a more sensitive test for the
virus. From our work, we have concluded that mature SV40
miRNA are not detected in human tissue samples, indicating that
they are not likely to contribute to mesothelioma tumourigenesis.
This can imply that the virus itself does not contribute to the
development of mesothelioma. Another interpretation is that,
because only the early SV40 genes are necessary to transform cells,
only these genes are expected to be expressed in mesotheliomas
(Carbone et al., 2008). The lack of false-positive results in an array
of cancerous and non-cancerous human tissue shows that these
assays are less vulnerable to laboratory contamination and cross-
reactivity. The consistent lack of detection of SV40 miRNAs
in human malignant mesotheliomas is indicative of a lack of associ-
ation of miRNA-producing infectious SV40 with this tumour type.
We cannot, however, completely exclude the association of human
mesothelioma with a transforming form of SV40.
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Figure 3 30 MicroRNA detected in SV40-infected HEK cells over time.
HEK cells were infected with SV40 in a laboratory separate from the site of
RNA preparation and PCR. Infections were performed with mock controls
in a blinded manner. At each time point, three samples of 1 10
6 cells
were harvested and total RNA was isolated. Fractions enriched for small
RNAs were reverse transcribed using the 30,5 0 and RNU48 assays.
Quantitative PCR was performed to measure the levels of miRNA relative
to the human control small RNA, RNU48. The relative quantification of
miRNA was performed according to the 2
 DDCt method, comparing
product amplified from SV40-infected human cells relative to RNU48.
Once it was determined that mock controls and 50 assays amplified no
product in infected HEK cells (data not shown), qPCR was repeated on
HEK cells at the four time points using the 30 and RNU48 assays on the
same plate for accurate relative quantification. Error bars represent s.e.
across triplicate infections.
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Figure 4 Quantitative RT–PCR of SV40 microRNA. Quantitative
RT–PCR was performed on 94 human malignant mesothelioma biopsies,
28 nonmalignant biopsies and 20 lung adenocarcinomas. Quantitative
PCR was performed to measure the levels of miRNA relative to the human
control small RNA, RNU48. The relative quantification of miRNA was
performed according to the 2
 DDCt method and measurements were
made relative to RNA isolated from HEK cells 72h after SV40 infection.
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